162 related articles for article (PubMed ID: 27795988)
1. Sex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center Experience.
Grupper A; Nestorovic EM; Daly RC; Milic NM; Joyce LD; Stulak JM; Joyce DL; Edwards BS; Pereira NL; Kushwaha SS
Transplant Direct; 2016 Oct; 2(10):e106. PubMed ID: 27795988
[TBL] [Abstract][Full Text] [Related]
2. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation.
Nath DS; Angaswamy N; Basha HI; Phelan D; Moazami N; Ewald GA; Mohanakumar T
Hum Immunol; 2010 Dec; 71(12):1191-6. PubMed ID: 20868717
[TBL] [Abstract][Full Text] [Related]
3. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
[TBL] [Abstract][Full Text] [Related]
4. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
[TBL] [Abstract][Full Text] [Related]
5. The clinical impact of donor-specific antibodies in heart transplantation.
Barten MJ; Schulz U; Beiras-Fernandez A; Berchtold-Herz M; Boeken U; Garbade J; Hirt S; Richter M; Ruhpawar A; Sandhaus T; Schmitto JD; Schönrath F; Schramm R; Schweiger M; Wilhelm M; Zuckermann A
Transplant Rev (Orlando); 2018 Oct; 32(4):207-217. PubMed ID: 29804793
[TBL] [Abstract][Full Text] [Related]
6. Association of MICA and AT1R antibodies with antibody-mediated rejection and cardiac allograft vasculopathy in a pediatric heart transplant recipient.
Chou-Wu E; Kemna M; Ross S; Youngs D; Law Y; Gimferrer I
Transpl Immunol; 2023 Jun; 78():101811. PubMed ID: 36889546
[TBL] [Abstract][Full Text] [Related]
7. The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection.
Clerkin KJ; Restaino SW; Zorn E; Vasilescu ER; Marboe CC; Mancini DM
J Heart Lung Transplant; 2016 Sep; 35(9):1059-66. PubMed ID: 27423693
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cardiac allograft vasculopathy in heart and heart-lung transplantations: a 15-year retrospective study.
Guihaire J; Mercier O; Flécher E; Aymami M; Fattal S; Chabanne C; Leroy Ladurie F; Lelong B; Cerrina J; Langanay T; Mussot S; Fabre D; De Latour B; Corbineau H; Verhoye JP; Dartevelle P; Leguerrier A; Fadel E
J Heart Lung Transplant; 2014 Jun; 33(6):636-43. PubMed ID: 24630860
[TBL] [Abstract][Full Text] [Related]
9. Late antibody-mediated rejection after heart transplantation: Mortality, graft function, and fulminant cardiac allograft vasculopathy.
Coutance G; Ouldamar S; Rouvier P; Saheb S; Suberbielle C; Bréchot N; Hariri S; Lebreton G; Leprince P; Varnous S
J Heart Lung Transplant; 2015 Aug; 34(8):1050-7. PubMed ID: 25956740
[TBL] [Abstract][Full Text] [Related]
10. Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.
Vaughn GR; Jorgensen NW; Law YM; Albers EL; Hong BJ; Friedland-Little JM; Kemna MS
Pediatr Transplant; 2018 Feb; 22(1):. PubMed ID: 29222866
[TBL] [Abstract][Full Text] [Related]
11. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
[TBL] [Abstract][Full Text] [Related]
13. Heart transplantation and anti-HLA antibodY: myocardial dysfunction and prognosis - HeartLAy study.
Sciaccaluga C; Natali BM; Righini FM; Sorini Dini C; Landra F; Mandoli GE; Sisti N; Menci D; D'Errico A; D'Ascenzi F; Focardi M; Bernazzali S; Maccherini M; Valente S; Cameli M
ESC Heart Fail; 2023 Oct; 10(5):2853-2864. PubMed ID: 37415291
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy.
Arora S; Andreassen A; Simonsen S; Gude E; Dahl C; Skaardal R; Hoel I; Geiran O; Gullestad L
Transplantation; 2007 Jul; 84(2):149-54. PubMed ID: 17667805
[TBL] [Abstract][Full Text] [Related]
15. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation.
Raichlin E; Edwards BS; Kremers WK; Clavell AL; Rodeheffer RJ; Frantz RP; Pereira NL; Daly RC; McGregor CG; Lerman A; Kushwaha SS
J Heart Lung Transplant; 2009 Apr; 28(4):320-7. PubMed ID: 19332257
[TBL] [Abstract][Full Text] [Related]
16. Routine C4d immunohistochemistry in cardiac allografts: Long-term outcomes.
Husain AN; Mirza KM; Fedson SE
J Heart Lung Transplant; 2017 Dec; 36(12):1329-1335. PubMed ID: 28988608
[TBL] [Abstract][Full Text] [Related]
17. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.
Delgado JF; Reyne AG; de Dios S; López-Medrano F; Jurado A; Juan RS; Ruiz-Cano MJ; Dolores Folgueira M; Gómez-Sánchez MÁ; Aguado JM; Lumbreras C
J Heart Lung Transplant; 2015 Aug; 34(8):1112-9. PubMed ID: 25940077
[TBL] [Abstract][Full Text] [Related]
19. Inhomogeneous myocardial stress perfusion in SPECT studies predicts future allograft dysfunction in heart transplant recipients.
Wenning C; Vrachimis A; Dell Aquila A; Penning A; Stypmann J; Schäfers M
EJNMMI Res; 2015 Dec; 5(1):51. PubMed ID: 26438347
[TBL] [Abstract][Full Text] [Related]
20. Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients.
Grupper A; AbouEzzeddine OF; Maleszewski JJ; Grupper A; Geske JR; Kremers WK; Kushwaha SS; Pereira NL
Clin Transplant; 2018 Sep; 32(9):e13349. PubMed ID: 29998506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
